Carbogen Inhalation Therapy for Epileptic Seizures: Mechanisms, Evidence, and Future Directions
CNS Neuroscience & Therapeutics · 2025-12 · 31 (12)
DOI: 10.1002/cns.70686 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift CNS Neuroscience & Therapeutics, online erschienen am 04.12.2025. Verfasst von Li Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Jingchu University of Technology, Jingmen, China. Hauptthemen laut MEDLINE: Carbon Dioxide, Seizures, Drug Resistant Epilepsy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 170 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hubei Provincial Department of Education Scientific Research Plan for Young Talent Project, Scientific Research Project of Jingchu University of Technology.
Abstract (Originalsprache)
Background
Drug‐resistant epilepsy (DRE) affects nearly one‐third of patients and remains a major unmet clinical need, despite advances in anti‐seizure medications (ASMs). Carbogen, a low‐concentration carbon dioxide (CO 2 ) and oxygen (O 2 ) gas mixture, has reemerged as a physiology‐based therapy owing to renewed insights into pH‐sensitive seizure mechanisms.
Methods
This review summarizes preclinical and clinical evidence on carbogen inhalation for seizure control. Mechanistic data on pH‐dependent ion channels, GABAergic inhibition, and adenosine signaling were condensed, and clinical outcomes across seizure types and inhalation protocols were compared for safety and efficacy.
Results
Carbogen induces short‐term respiratory acidosis, lowering brain extracellular pH to activate acid‐sensitive ion channels (e.g., ASIC1a and NaV1.2), enhance GABAergic inhibition, and boost adenosine signaling. These effects are rapid, reversible, and distinct from conventional ASMs. Preclinical studies show strong seizure suppression, especially under hyperventilation‐induced alkalosis. Clinically, brief low‐dose inhalation (5% CO 2 for ≤ 3 min) is effective and well tolerated in focal and absence seizures, whereas earlier high‐concentration protocols caused adverse effects. Efficacy varies by seizure type: benefits in nonconvulsive status epilepticus (NCSE) are limited, and the CARDIF trial found no advantage for pediatric febrile seizures. Ongoing work, such as the CRESCENT trial, is exploring carbogen as an adjunct therapy for pediatric convulsive status epilepticus (CSE).
Conclusions
Evidence supports carbogen's therapeutic promise and highlights the need for precise patient selection, controlled delivery, and comprehensive safety testing. Future research should develop biomarker‐guided, closed‐loop systems and test synergy with established ASMs to advance carbogen as a mechanism‐based therapy within precision epilepsy care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medicine, Jingchu University of Technology, Jingmen, China.
- Department of Radiation Biology, Faculty of Preventive Medicine, the Ministry of Education Key Lab of Hazard Assessment and Control in Special Operational Environment, The Fourth Military Medical University, Xi'an, Chin…
- The Brain Cognition and Brain Disease Institute (BCBDI), Shenzhen Key Laboratory of Viral Vectors for Biomedicine, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen-Hong Kong Institute of…
- University of Chinese Academy of Sciences, Beijing, China.
- Wuhan National Laboratory for Optoelectronics, Huazhong University of Science and Technology, Wuhan, China.
- Center for Excellence in Brain Science and Intelligence Technology, Chinese Academy of Sciences, Shanghai, China.
ORCID-Profile: Li Wang, Yue Liu, Wenwen Ding, Meng Yang, Qing Liu, Fuqiang Xu
Förderung
- Hubei Provincial Department of Education Scientific Research Plan for Young Talent Project
- Scientific Research Project of Jingchu University of Technology
Zitieren
APA
Wang, L., Liu, Y., Ding, W., Yang, M., Liu, Q., & Xu, F. (2025). Carbogen Inhalation Therapy for Epileptic Seizures: Mechanisms, Evidence, and Future Directions. CNS Neuroscience & Therapeutics, 31(12). https://doi.org/10.1002/cns.70686
Vancouver
Wang L, Liu Y, Ding W, Yang M, Liu Q, Xu F. Carbogen Inhalation Therapy for Epileptic Seizures: Mechanisms, Evidence, and Future Directions. CNS Neuroscience & Therapeutics. 2025;31(12). doi:10.1002/cns.70686
BibTeX
@article{Wang2025,
author = {Wang, Li and Liu, Yue and Ding, Wenwen and Yang, Meng and Liu, Qing and Xu, Fuqiang},
title = {Carbogen Inhalation Therapy for Epileptic Seizures: Mechanisms, Evidence, and Future Directions},
journal = {CNS Neuroscience & Therapeutics},
year = {2025},
volume = {31},
number = {12},
doi = {10.1002/cns.70686}
}
EUVIMED